Papers

6

Total Citations

289

H-Index

6

About

Dr. Ardeshir R. Rastinehad is a leading figure in urologic oncology, renowned for his pioneering work in prostate cancer imaging and image-guided interventions. His research centers on the integration of multiparametric MRI (mpMRI) and advanced biopsy techniques to improve cancer detection and treatment planning. A landmark 2013 study (155 citations) demonstrated the superiority of 3 Tesla MRI with an endorectal coil for localizing prostate cancer, correlating imaging findings with whole-mount histopathology to set a new standard for diagnostic accuracy. Dr. Rastinehad has also been instrumental in evaluating fusion biopsy technologies, showing in a 2019 study that mpMRI-guided fusion biopsy reduces the risk of Gleason grade group downgrading compared to standard 12-core biopsy—a critical insight for treatment decisions. Beyond diagnostics, his work on robot-assisted surgery safety, including a comprehensive review of the FDA MAUDE database (92 citations), has highlighted device-related risks and improved patient safety protocols. His contributions extend to image guidance during radical prostatectomy, where he has explored the role of mpMRI in surgical planning. With over 300 citations across his most influential papers, Dr. Rastinehad’s research continues to shape the landscape of precision prostate cancer care.

Research Focus

Key Achievements

6
H-Index
6
Papers
289
Total Citations
48
Avg Citations/Paper
🏆 Most Cited Paper
Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: Correlation with whole-mount histopathology
155 citations · 2013
📈 Most Prolific Year: 2008 (2 Papers)
🤝 Key Collaborators: 44
🏛 Institutions: National Institutes of Health, Northwell Health, Icahn School of Medicine at Mount Sinai

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago